MIRA Pharmaceuticals (MIRA) Competitors $1.50 +0.03 (+2.04%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.48 -0.02 (-1.33%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. ZURA, SAVA, HLVX, COYA, CHRS, MGNX, CLYM, PLRX, ANIX, and ONCYShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Zura Bio (ZURA), Cassava Sciences (SAVA), HilleVax (HLVX), Coya Therapeutics (COYA), Coherus Oncology (CHRS), MacroGenics (MGNX), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Its Competitors Zura Bio Cassava Sciences HilleVax Coya Therapeutics Coherus Oncology MacroGenics Climb Bio Pliant Therapeutics Anixa Biosciences Oncolytics Biotech Zura Bio (NASDAQ:ZURA) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Do analysts recommend ZURA or MIRA? Zura Bio presently has a consensus price target of $14.17, indicating a potential upside of 753.41%. MIRA Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 1,033.33%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than Zura Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is ZURA or MIRA more profitable? Zura Bio's return on equity of -47.44% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -47.44% -38.81% MIRA Pharmaceuticals N/A -329.63%-271.22% Does the media prefer ZURA or MIRA? In the previous week, Zura Bio had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 8 mentions for Zura Bio and 7 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.89 beat Zura Bio's score of 0.58 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MIRA Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ZURA or MIRA? Zura Bio has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Which has better valuation & earnings, ZURA or MIRA? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$45.39M-$0.70-2.37MIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-2.94 Do insiders and institutionals believe in ZURA or MIRA? 61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryZura Bio beats MIRA Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.03M$3.10B$5.69B$9.81BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-3.0620.8931.0825.11Price / SalesN/A363.22466.03115.16Price / CashN/A42.3037.4059.05Price / Book11.548.659.096.18Net Income-$7.85M-$54.65M$3.26B$265.11M7 Day Performance8.70%6.56%7.31%4.20%1 Month Performance-19.79%7.53%5.43%2.00%1 Year Performance-22.28%13.69%30.60%23.76% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals3.2659 of 5 stars$1.50+2.0%$17.00+1,033.3%-20.2%$28.03MN/A-3.062Earnings ReportShort Interest ↓ZURAZura Bio3.6804 of 5 stars$1.46-2.7%$14.33+881.7%-49.4%$102.56MN/A-2.093News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionSAVACassava Sciences2.1031 of 5 stars$2.29+8.0%$54.50+2,279.9%-91.8%$102.41MN/A-1.5330News CoverageEarnings ReportHLVXHilleVax1.6262 of 5 stars$2.07+1.5%$2.00-3.4%+14.9%$102.29MN/A-0.9620News CoverageHigh Trading VolumeCOYACoya Therapeutics1.6547 of 5 stars$6.34+4.1%$16.50+160.3%+22.8%$101.86M$3.69M-5.936News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionCHRSCoherus Oncology4.1612 of 5 stars$0.87-1.1%$4.68+439.6%-32.3%$101.77M$266.96M-0.77330MGNXMacroGenics4.3293 of 5 stars$1.64+3.8%$5.33+225.2%-51.5%$99.68M$152.43M-1.84430Trending NewsEarnings ReportAnalyst ForecastCLYMClimb Bio3.5777 of 5 stars$1.70+17.2%$9.00+429.4%N/A$97.99MN/A-0.719News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumePLRXPliant Therapeutics3.8986 of 5 stars$1.70+7.6%$13.31+683.1%-87.5%$96.99M$1.58M-0.4790ANIXAnixa Biosciences2.5864 of 5 stars$3.26+8.3%$9.00+176.1%-6.9%$96.96M$210K-8.585ONCYOncolytics Biotech1.8613 of 5 stars$0.88-10.8%$4.33+390.7%+11.3%$96.43MN/A-3.0530Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies Zura Bio Competitors Cassava Sciences Competitors HilleVax Competitors Coya Therapeutics Competitors Coherus Oncology Competitors MacroGenics Competitors Climb Bio Competitors Pliant Therapeutics Competitors Anixa Biosciences Competitors Oncolytics Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access